Navigation Links
OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
Date:10/30/2013

ormation from the quarterly call by following the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our expected timelines for our SYNERGY and Borealis-1 trials. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
2. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
5. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
6. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
8. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
9. Hanger Reports Third Quarter 2013 Results
10. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
11. Questcor Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CHAPEL HILL, N.C. , Nov. 21, 2014 ... the healthcare system. Undoubtedly, the growing influence of ... and spend for marketing interactions. Now, more than ... and retain patients for medical products is essential. ... benchmarking firm, Best Practices, LLC, benchmarked companies spent ...
(Date:11/21/2014)... , Nov. 21, 2014  Tandem Diabetes Care ... a medical device company and manufacturer of the ... partnership with Tidepool, a non-profit dedicated to improving ... software platform that increases diabetes data accessibility. This ... which is currently under development, to download and ...
(Date:11/21/2014)... 2014  Heated dialogue in recent months about the ... treatments to Gilead,s new hepatitis C drug Harvoni® – ... questioning what it means to put a price on ... And while drug pricing is one of the most ... a general business and ethical standpoint – it is ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5
... and JERUSALEM, Sept. 14, 2011 Chiasma, Inc., a privately ... CEO, will present an overview of the Company at the ... York, New York, on Monday, September 19, 2011 at 1:30 ... oral form of octreotide acetate being developed first for the ...
... Medical Technologies, Inc. and the Physician Services technology ... announced an agreement for INHS to provide Greenway,s ... solution PrimeSUITE® 2011 to hospital systems ... network interoperability. Established more than a ...
Cached Medicine Technology:Chiasma to Present at the UBS Global Life Sciences Conference 2Greenway Partners With INHS to Advance EHR Adoption 2Greenway Partners With INHS to Advance EHR Adoption 3
(Date:11/22/2014)... 2014 A petition seeking a ban ... in minimally-invasive hysterectomies and fibroid removal surgeries has ... of October, Bernstein Liebhard LLP reports. According to ... November 21st, 2014. That represents an increase of 456 ... on to the campaign.* , The campaign to ban ...
(Date:11/22/2014)... Nov. 22, 2014 (HealthDay News) -- The wide variety ... pose a threat for people with food allergies, an ... are so many types of food allergies that it ... the holidays," Dr. Guha Krishnaswamy, director of allergy and ... in a hospital news release. "If you know ...
(Date:11/22/2014)... 2014 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) ... allegedly developed Type 2 diabetes due to its use ... now underway in U.S. District Court, District of South ... the litigation will convene its next Status Conference on ... Lead Counsel for Plaintiffs and Defendants to meet and ...
(Date:11/22/2014)... 22, 2014 Hastings and Hastings, a ... experience announces providing clients with the option of leaving ... clients a flexible, intuitive and easy to navigate website ... access to Google + allows clients to research the ... a more informed decision when retaining an attorney. Those ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Forbes ... are pleased to announce that Ashley Lombardo and ... #PayItForward contest. , Ms. Lombardo entered friend Candy ... Innovations. She wrote of how her friend is courageously ... as a single mom. Despite medical bills piling up ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2
... MD) In a study published today in the ... from the Kennedy Krieger Institute found differences in the ... Disorder (ADHD). Results showed the region of the brain ... these children than in typically developing children. Novel for ...
... , AUGUSTA, Ga. Researchers want to turn back ... better bone. , Bone-weakening osteoporosis results in a fracture ... Foundation. The right nutrients resulting in the right signals ... stronger bones longer and reducing the death and disability ...
... , THURSDAY, June 9 (HealthDay News) -- A natural compound ... from aging and illness, according to the results of a study ... in apple skin called ursolic acid, according to Dr. Christopher Adams, ... Adams and colleagues first identified 63 genes that change in response ...
... to try to reduce racial and ethnic disparities in the ... the problem at any of the state,s 66 acute-care hospitals, ... effectiveness of the state,s novel approach. While the study, ... (June 9, 2011), found that racial and ethnic inequities for ...
... cardit slips into a wallet or pursebut it could mean the ... MyCare Card stores personal medical data (e.g. information on existing medical ... USB port, enabling the data to be accessed in just a ... type to have been trialled in the UK. This working ...
... WEDNESDAY, June 8 (HealthDay News) -- Brain scans that detect early ... as soon as this year, researchers reported this week, though it ... help for those with the disease. "You,ll get ... people who want to know what,s going on when their memory ...
Cached Medicine News:Health News:Brain imaging study of preschoolers with ADHD detects brain differences linked to symptoms 2Health News:Researchers work to turn back the clock on bone-producing stem cells 2Health News:Researchers work to turn back the clock on bone-producing stem cells 3Health News:Researchers work to turn back the clock on bone-producing stem cells 4Health News:Apples Help Keep Muscles Strong, Mouse Study Finds 2Health News:Pioneering hospital pay-for-performance program falls short of its goals 2Health News:MyCare -- the 'card' that could save your life 2Health News:Brain Scans to Spot Alzheimer's May Be Available This Year 2
... a test for the presence of blood is ... in guaiac to quinones, resulting in the production ... the heme portion of the hemoglobin molecule can ... of oxygen from hydrogen peroxide which in turn ...
... years, the Hemoccult fecal occult blood test (FOBT) ... in stool specimens as an early indication of ... products many of which were conducted over ... participants- have been published in leading medical journals ...
... scientific principles supporting the effectiveness and accuracy ... upon extensive clinical studies. As a woman ... estrogen level increases, thereby, elevating the salt ... as saliva is allowed to dry, crystalization ...
Inquire...
Medicine Products: